Nanobiotix Files 6-K with SEC
Ticker: NBTX · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1760854
Sentiment: neutral
Topics: sec-filing, 6-K, compliance
TL;DR
Nanobiotix files routine SEC 6-K, confirming foreign private issuer status.
AI Summary
Nanobiotix S.A. filed a Form 6-K on September 2, 2025, reporting its status as a foreign private issuer. The company, based in Paris, France, is subject to the reporting requirements of the U.S. Securities and Exchange Commission under the 1934 Act. Nanobiotix is incorporated and operates under French law, with its fiscal year ending on December 31st.
Why It Matters
This filing indicates Nanobiotix's ongoing compliance with U.S. securities regulations as a foreign private issuer, which is crucial for its investors and potential U.S. market access.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the Form 6-K
- 001-39777 (company) — SEC File Number for Nanobiotix S.A.
- 20250902 (date) — Filing date and period of report
- 60 Rue de Wattignies 75012 Paris, France (company) — Principal executive office address
FAQ
What type of filing is Nanobiotix S.A. submitting?
Nanobiotix S.A. is submitting a Form 6-K, which is a Report of Foreign Private Issuer.
When was this Form 6-K filed?
The Form 6-K was filed on September 2, 2025.
What is Nanobiotix S.A.'s SEC file number?
Nanobiotix S.A.'s SEC file number is 001-39777.
Where is Nanobiotix S.A.'s principal executive office located?
Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Does Nanobiotix S.A. file its annual reports under Form 20-F?
Yes, Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-09-02 16:15:04
Filing Documents
- f6k_090225.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-25-005677.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: September 2, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer